Synthetic peptide (the amino acid sequence is considered to be commercially sensitive) corresponding to Human Bcl10 aa 200 to the C-terminus (C terminal).
WB: Raji cell lysate, Hela cell lysate
IHC: Human hepatocellular and lungcarcinoma
ICC/IF: Raji cells
IP: Ramos cell lysate
This product is a recombinant rabbit monoclonal antibody.
Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated ‘PUR’ on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
1/100 - 1/250.
1/1000 - 1/5000. Detects a band of approximately 32 kDa (predicted molecular weight: 31 kDa).
1/20 - 1/50.
FunctionPromotes apoptosis, pro-caspase-9 maturation and activation of NF-kappa-B via NIK and IKK. May be an adapter protein between upstream TNFR1-TRADD-RIP complex and the downstream NIK-IKK-IKAP complex. Is a substrate for MALT1.
Involvement in diseaseNote=A chromosomal aberration involving BCL10 is recurrent in low-grade mucosa-associated lymphoid tissue (MALT lymphoma). Translocation t(1;14)(p22;q32). Although the BCL10/IgH translocation leaves the coding region of BCL10 intact, frequent BCL10 mutations could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions. Note=Defects in BCL10 are involved in various types of cancer.
Sequence similaritiesContains 1 CARD domain.
Post-translational modificationsPhosphorylated. Phosphorylation results in dissociation from TRAF2 and binding to BIRC2/c-IAP2.
Cellular localizationCytoplasm > perinuclear region. Membrane raft. Appears to have a perinuclear, compact and filamentous pattern of expression. Also found in the nucleus of several types of tumor cells. Colocalized with DPP4 in membrane rafts.
Immunofluorescence staining of Raji cells with purified ab33905 at a working dilution of 1/100, counter-stained with DAPI. The secondary antibody was Alexa Fluor® 488 goat anti-rabbit (ab150077), used at a dilution of 1/1000. ab7291, a mouse anti-tubulin antibody (1/1000), was used to stain tubulin along with ab150120 (Alexa Fluor® 594 goat anti-mouse, 1/1000), shown in the top right hand panel. The cells were fixed in 4 % PFA and permeabilized using 0.1% Triton X 100. The negative controls are shown in bottom middle and right hand panels - for negative control 1, purified ab33905 was used at a dilution of 1/500 followed by an Alexa Fluor® 594 goat anti-mouse antibody (ab150120) at a dilution of 1/500. For negative control 2, ab7291 (mouse anti-tubulin) was used at a dilution of 1/500 followed by an Alexa Fluor® 488 goat anti-rabbit antibody (ab150077) at a dilution of 1/400.
Immunohistochemical staining of paraffin embedded human lung carcinoma with purified ab33905 at a working dilution of 1/50. The secondary antibody used is ab97051, a goat anti-rabbit IgG (H&L) at a dilution of 1/500. The sample is counter-stained with hematoxylin. Antigen retrieval was perfomed using Tris-EDTA buffer, pH 9.0. PBS was used instead of the primary antibody as the negative control, and is shown in the inset.
ab33905 (purified) at 1/20 immunoprecipitating Bcl10 in 10 μg Ramos cell lysate (Lanes 1 and 2, observed at 32 kDa). Lane 3 - Rabbit monoclonal IgG (ab172730). For western blotting, HRP Veriblot for IP (ab131366) was used as the secondary antibody (1/10 000). Blocking buffer and concentration: 5% NFDM/TBST Dilution buffer and concentration: 5% NFDM/TBST
References for Anti-Bcl10 antibody [EP606Y] (ab33905)
This product has been referenced in:
Meininger I et al. Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells. Nat Commun7:11292 (2016).
Read more (PubMed: 27068814) »
Mc Guire C et al. Pharmacological inhibition of MALT1 protease activity protects mice in a mouse model of multiple sclerosis. J Neuroinflammation11:124 (2014).
Read more (PubMed: 25043939) »